Received Apr 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 4T93R | — |
Inappropriate Vaccination Schedule (less than 6 months after first dose); This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 70-year-old female patient who received HAV (Havrix) (batch number 4T93R, expiry date 11-JUL-2026) for prophylaxis. Previously administered products included Havrix (received 1st dose on 12th December 2024, batch number : 4T93R and expiry date:11-JUL-2026 00:00). On 22-APR-2025, the patient received the 2nd dose of Havrix. On 22-APR-2025, an unknown time after receiving Havrix, the patient experienced drug dose administration interval too short (Verbatim: Inappropriate Vaccination Schedule (less than 6 months after first dose)). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date:22-APR-2025 Pharmacist called to report a patient was vaccinated for the second dose on month four after the first dose instead of sixth month after the first dose. The reporter asked if they need to revaccinate. The vaccination date (first and second dose), vaccine detail (first and second dose) and patient demographics were obtained in this call. No further information was obtained in this call. The Vaccine Administration Facility was the same as Primary Reporter. The reporter consented to follow up. The patient received 2nd dose of Havrix earlier than the recommended schedule, which led to shortening of vaccination schedule.